US20100196334A1 - Cell Suspension Preparation Technique and Device - Google Patents

Cell Suspension Preparation Technique and Device Download PDF

Info

Publication number
US20100196334A1
US20100196334A1 US12/699,554 US69955410A US2010196334A1 US 20100196334 A1 US20100196334 A1 US 20100196334A1 US 69955410 A US69955410 A US 69955410A US 2010196334 A1 US2010196334 A1 US 2010196334A1
Authority
US
United States
Prior art keywords
patient
cells
tissue
suitable
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/699,554
Inventor
Fiona M. Wood
Marie L. Stoner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AVITA MEDICAL Ltd
Original Assignee
MCCOMB FOUNDATION Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AUPR2989A priority Critical patent/AUPR298901A0/en
Priority to AUPR2989 priority
Priority to US28152701P priority
Priority to US10/068,299 priority patent/US20020106353A1/en
Application filed by MCCOMB FOUNDATION Inc filed Critical MCCOMB FOUNDATION Inc
Priority to US12/699,554 priority patent/US20100196334A1/en
Assigned to MCCOMB FOUNDATION, INC. reassignment MCCOMB FOUNDATION, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STONER, MARIE L., WOOD, FIONA M.
Publication of US20100196334A1 publication Critical patent/US20100196334A1/en
Assigned to AVITA MEDICAL LTD reassignment AVITA MEDICAL LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: THE MCCOMB FOUNDATION, INC.
Assigned to AVITA MEDICAL LTD reassignment AVITA MEDICAL LTD CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME FROM AND PROPERTY DETAILS LISTED ON SCHEDULE A PREVIOUSLY RECORDED ON REEL 027297 FRAME 0634. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECTIVE ASSIGNMENT. Assignors: MCCOMB FOUNDATION INC
Assigned to MCCOMB FOUNDATION INC reassignment MCCOMB FOUNDATION INC CORRECTIVE ASSIGNMENT TO CORRECT THE FIRST ASSIGNOR'S NAME AND ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 024441 FRAME: 0541. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: STONER, MARIE L., WOOD, FIONA M.
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/10Hair or skin implants
    • A61F2/105Skin implants, e.g. artificial skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M45/00Means for pre-treatment of biological substances
    • C12M45/02Means for pre-treatment of biological substances by mechanical forces; Stirring; Trituration; Comminuting
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M45/00Means for pre-treatment of biological substances
    • C12M45/06Means for pre-treatment of biological substances by chemical means or hydrolysis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M45/00Means for pre-treatment of biological substances
    • C12M45/09Means for pre-treatment of biological substances by enzymatic treatment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M45/00Means for pre-treatment of biological substances
    • C12M45/22Means for packing or storing viable microorganisms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/02Separating microorganisms from the culture medium; Concentration of biomass
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602Vertebrate cells
    • C12N5/0625Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629Keratinocytes; Whole skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/09Body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/75General characteristics of the apparatus with filters
    • A61M2205/7545General characteristics of the apparatus with filters for solid matter, e.g. microaggregates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/98Xeno-free medium and culture conditions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/99Serum-free medium
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00Methods for the dissociation of cells, e.g. specific use of enzymes

Abstract

The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for grafting to a patient. In applying the method and/or in using the device, donor tissue is harvested, subjected to a cell dissociation treatment, cells suitable for grafting back to a patient are collected and dispersed in a solution that is suitable for immediate dispersion over the recipient graft site.

Description

    RELATED APPLICATIONS
  • The present invention is a continuation of U.S. patent application Ser. No. 10/068,299, filed Feb. 6, 2002, which claims priority to and benefit of Australian Provisional Patent Application PR2989, filed Feb. 7, 2001 and U.S. Provisional Patent Application No. 60/281,527, filed Apr. 4, 2001, all of which are incorporated herein by reference in their entirety.
  • FIELD OF THE INVENTION
  • This invention relates to a simple, rapid and cost effective technique for grafting of cells, and in particular to a device for preparing a suspension of cells from a tissue sample obtained from a donor site and applying that suspension of cells to a recipient site.
  • BACKGROUND
  • There are many methods of treating wounds known to those skilled in the art. For example, skin grafting techniques exist which aim to reconstruct the skin covering areas of the body where there is either damage or defects to the skin. In general, these types of grafts are classified according to their host-donor relationship and by their thickness. The most clinically applied graft is the autologous graft, whereby tissue is taken from one area of the body and applied to another area. The grafted tissue then develops a new blood supply and attaches to the underlying tissues.
  • There are several types of skin grafts presently used, including split-thickness, full-thickness grafts, and micro-grafting. Each of these graft types must be prepared using certain techniques, and each one has its inherent advantages and disadvantages. Split-thickness grafts often require considerable skill, time and expensive equipment to perform. Further, donor sites are painful, result in scarring and limit the area able to be covered. Although they may be more successful than full-thickness grafts, they are usually less cosmetically attractive. Full-thickness grafts require less skill or expensive equipment, and their cosmetic appearance is better than that of split-thickness grafts. However, full-thickness grafts do not “take” as well as split-thickness grafts. Micro-grafts are more easily accomplished and require no special instruments. However, their cosmetic appearance is not as good as other techniques, as the resulting scarring is unacceptable.
  • A variation to the above grafting techniques is the mesh graft, which is a type of split-thickness or full-thickness skin graft in which parallel rows of slits are cut in the tissue being treated. Some of the advantages of mesh grafts include: a greater coverage of the effected area, drainage of blood or serum from under the graft, and increased conformity of the graft to uneven recipient areas. This technique has been very successful, with 90 to 100 percent “take” when the grafts have been applied on healthy granulation beds.
  • An alternative to split-skin grafting is to form a blister under suction at a donor site and transplant to the recipient site. The production of blisters to treat wounds has been used since the 1960s. The blisters are produced by a suction device, such as Dermavac™, at a suction pressure of approximately 250-300 mmHg for 1-2 hours. The blisters are then cut off and placed on the wound. The healing time is around 10-14 days. There are several disadvantages of this method such as the amount of time required to prepare the graft is too long and the graft may not result in re-pigmentation of the area; or uneven pigmentation is common around the edges of the area of treatment.
  • Micro-grafting has become a more common approach for large area cover and involves the “snipping off” of a number of very small sections of tissue from a donor site and applying then to a dressing, which is in turn applied to the wound area.
  • The most advanced technology for the generation of a tissue in vitro is to culture epidermis. Cultured epithelial autografts (CEA) are an important adjunct in the coverage of burns and other situations in which large areas of the body's surface experience skin loss. There are many centers throughout the world with tissue culture facilities whose aim is to produce autologous epithelial grafts for use in a wide variety of applications. The usefulness and application of CEA is related to its ability to achieve confluent cells sheets suitable for grafting. This technique overcomes many of the disadvantages of the previous treatments described above. For example, cultured epithelial autografts reduce the demand for donor sites. However, these autografts are slow growing and require time for culturing of the grafts, which often exceeds the time of preparation of the recipient's sites.
  • The present invention provides a cellular suspension together with a method for preparing that suspension and a device for its preparation each of which seek to ameliorate one or more of the disadvantages associated with prior art grafting technology.
  • SUMMARY OF THE INVENTION
  • The subject invention relates to a unique cell suspension and method for its preparation that is rapid, efficient and simple to prepare and apply. It also relates to a method for treating a patient using the unique cell suspension and to an apparatus suitable for use in the method preparation. Use of the described device while not essential for practicing the method of the invention has been found to significantly reduce the complexity associated with the use of conventional grafting technology such as CEA.
  • According to a first aspect of the invention there is provided a method for preparing a cell suspension suitable for application to a patient, which method comprises the steps of:
  • (a) subjecting a tissue sample including cells suitable for grafting to a patient, to at least a physical and or chemical dissociating means capable of dissociating cellular stratum in the tissue sample;
  • (b) removing the tissue sample from the presence of the tissue dissociating means used in step (a) and harvesting in the presence of a nutrient solution cells from the tissue sample, cells suitable for grafting on to a patient wherein the nutrient solution is (i) free of xenogenic serum, (ii) capable of maintaining the viability of the cells until applied to a patient and (iii) is suitable for direct application to a region on a patient undergoing tissue grafting; and
  • (c) filtering the cellular suspension produced according to step (b) to remove large cellular conglomerates.
  • In a preferred form of the invention the dissociating means is of a chemical nature such as an enzyme which is capable of disrupting cellular bonding like for example trypsin. Further, preferably the filtered cellular suspension is diluted to an appropriate cell density using a nutrient solution, which may be anything from a basic salt solution to a more complex nutrient solution.
  • According to a second aspect of the invention there is provided a cell suspension produced according to the above method. Preferably the cells in the suspension are autologous cells (i.e. they are isolated from the patient requiring an autograft). The inventors have observed that by removing xenogenic serum from the cell suspension there is less likelihood of transmission of infection and xenogenic reactions between a patient and the serum are eliminated. Another feature of the cell suspension produced according to the above method is that the tissue sample used to isolate the cells in the suspension is removed from the enzyme solution before the cells are harvested. When cells are exposed to enzymes capable of damaging inter-cellular adhesion the viability of the cellular suspension decreases over time thereby reducing the efficiency of the grafting when applied to a patient. The cell suspension produced according to the above method has been observed to possess greater cellular viability compared to comparative methods that harvest the cells at regular intervals whilst the tissue is immersed in the presence of enzymes like trypsin.
  • According to a third aspect of the invention there is provided a method of treating a patient in need of graft surgery, said method comprising the steps of:
  • (a) preparing an cell suspension according to the above method;
  • (b) administering the suspension directly to a region on the patient that requires a cell graft in a manner that facilitates spreading of the cell suspension in a relatively even distribution over the graft region.
  • In an alternate form, the invention consists in the use of a cellular suspension suitable for grafts, which suspension is prepared according to the following steps:
  • (a) subjecting a tissue sample including cells suitable for grafting to a patient, to an enzyme suitable for dissociating cohesive pieces of the tissue stratum in the sample;
  • (b) removing the sample from the enzyme solution used in step (a) and harvesting in the presence of a nutrient solution cells from the tissue sample, which cells are suitable for grafting on to a patient wherein the nutrient solution is (i) free of xenogenic serum, (ii) capable of maintaining the viability of the cells until applied to a patient and (iii) is suitable for direct application to a region on a patient undergoing tissue grafting;
  • (c) filtering the cellular suspension produced according to step (b) to remove large cellular conglomerates;
  • for the preparation of medicament suitable for the treatment of tissue disorders requiring grafting.
  • According to a fourth aspect of the invention there is provided an apparatus for developing a tissue regeneration solution, said apparatus comprising:
  • (a) a heating means suitable for heating an enzyme solution to a required temperature and which is capable of maintaining that solution at the desired temperature for a suitable amount of time; and
  • (b) a filter recess comprising a filter means capable of separating large cellular congregates from a cellular suspension.
  • When the enzyme solution is placed in contact with the heating means it is preferably heated in a manner that avoids localized heating within the solution.
  • A further aspect of the invention relates to a method for preparing a cell suspension suitable for application to a patient. The method can include the following steps:
  • (a) harvesting cells suitable for grafting to a patient from a tissue sample from a first tissue region of the patient, wherein a cellular stratum in the tissue sample is physically and/or chemically dissociated, wherein the cells are harvested in a nutrient solution that is (i) free of serum xenogenic to the patient, (ii) capable of maintaining viability of the harvested cells, and (iii) suitable for direct application to a second tissue region of the patient; and
  • (b) filtering the harvested cells to remove cellular conglomerates greater than 200 μM, thereby producing a cell suspension comprising viable cells autologous to the patient, wherein the cell suspension is free of serum xenogenic to the patient and free of cellular conglomerates greater than 200 μM.
  • In some embodiments, the first tissue region is the same as the second tissue region. The first tissue region can be a different region than the second tissue region and can be selected to match the second tissue region. In some embodiments, the method further includes multiplicating cells in situ.
  • Another aspect of the invention relates to a method for delivering a cell suspension to a patient in need of graft surgery. The method can include:
  • (a) harvesting cells suitable for grafting to the patient from a tissue sample of the patient in a nutrient solution that is (i) free of serum xenogenic to the patient, (ii) capable of maintaining viability of the harvested cells, and (iii) suitable for direct application to a second tissue region of the patient;
  • (b) filtering the harvested cells to remove cellular conglomerates greater than 200 μM to produce a cell suspension; and
  • (c) administering the cell suspension to a tissue region of the patient in need of a cell graft.
  • In some embodiments, the administering step includes spreading the cell suspension over the tissue region in a substantially even distribution. In certain embodiments, the cell suspension can be sprayed or dripped through a nozzle. In some embodiments, the method further includes multiplicating cells in situ.
  • In another aspect, the invention includes a method for expanding a population of cells in situ. The method includes
  • (a) harvesting cells suitable for grafting to a patient from a tissue sample of the patient, wherein a cellular stratum in the tissue sample is physically and/or chemically dissociated, wherein the cells are harvested in a nutrient solution that is (i) free of serum xenogenic to the patient, (ii) capable of maintaining viability of the harvested cells, and (iii) suitable for direct application to a second tissue region of the patient;
  • (b) filtering the harvested cells to remove cellular conglomerates greater than 200 μM to produce a cell suspension;
  • (c) applying the cell suspension to a tissue region of the patient in need of a cell graft; and
  • (d) permitting cells to expand in situ under conditions suitable for cellular multiplication.
  • Yet another aspect of the invention relates to an apparatus for delivering cells to a patient in need of graft surgery. The apparatus can include an aerosol bottle adapted to deliver a medium comprising a nutrient solution that is (i) free of serum xenogenic to the patient, (ii) capable of maintaining viability of a cell, and (iii) suitable for direct application to a tissue region of the patient. The medium can further include cells that are harvested from a tissue sample of the patient and free of cellular conglomerates greater than 200 μM.
  • In some embodiments, the aerosol bottle includes a syringe for collecting the medium and a nozzle attached to the syringe for spraying or dripping the medium to the tissue region of the patient. In some embodiments, the apparatus further includes a filter adapted to remove cellular conglomerates greater than 200 μM.
  • Other aspects and advantages of the invention will become apparent to those skilled in the art from a review of the ensuing description, which proceeds with reference to the following illustrative drawings.
  • BRIEF DESCRIPTION OF DRAWINGS
  • FIG. 1 illustrates a perspective view of the apparatus with the lid open and the second member in place.
  • FIG. 2 illustrates a perspective view of the apparatus with the lid open and the second member removed and inverted.
  • FIG. 3A illustrates a perspective view of the first member of the apparatus.
  • FIG. 3B illustrates a perspective rear view of the first member of the apparatus.
  • FIG. 4 illustrates a perspective view of the base of the apparatus.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variation and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in the specification, individually or collectively and any and all combinations or any two or more of the steps or features.
  • The present invention is not to be limited in scope by the specific embodiments described herein, which are intended for the purpose of exemplification only. Functionally equivalent products, compositions and where appropriate methods are clearly within the scope of the invention as described herein.
  • Throughout this specification and the claims that follow, unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.
  • Having regard to the above, this invention provides a unique method and or device suitable for producing a transplantable cellular suspension of living tissue suitable for grafting to a patient. In applying the method and/or in using the device donor tissue is harvested, subjected to a tissue dissociating means, cells suitable for grafting back to a patient are collected and dispersed in a solution that is suitable for immediate dispersion over the recipient graft site.
  • The subject invention has many advantages over the prior art some of which are illustrated in the following paragraphs.
  • 1. It provides a time efficient method for supplying a cellular cover to a tissue in a clinical setting. That is, cells are available when needed at the time of surgery. This is achievable because there is a very short preparation period of the cells, thus allowing grafting to be performed peri-operatively or in the rooms of a specialist physician or General Practitioner.
  • 2. It provides a method and an apparatus which significantly reduces the complexity associated with the use of conventional CEA's and is particularly useful in cases of burn injury that have presented late. In some instances, cells are unavailable at the time of surgery, either due to delayed referral of a patient with an unhealed burn or simply because the time needed for culturing of the grafts had exceeded that for preparation of the recipient would bed. The present invention ameliorates the issue of graft preparation time.
  • 3. It aids in the achievement of rapid cell coverage in areas of injury and donor sites. It provides a means for reducing the size of donor sites—the biopsy donor site is markedly smaller than a split skin graft donor site and reduces or eliminates the use of split skin graft donor sites; improves expansion rate of cell coverage; improves the rate of healing of small burns; is useful for small areas of skin reconstructions, such as scars; and improves scar quality.
  • 4. It ameliorates problems associated with the use of solutions used during conventional tissue culture process. According to the method of preparation and treatment the cells used in a graft are suspended in a nutrient solution free of xenogenic serum. That suspension is then placed directly onto the recipient site.
  • 5. It provides a means for the treatment of various skin disorders or diseases. For example, it may be used for the following: epidermal resurfacing, replacement after skin loss, site match-up during re-pigmentation of an area of skin, treatment of burn wounds, leukoderma, vitiligo, piebaldism, in the treatment of scars—for example, caused through incorrect wound healing, improper scar direction or scar distortion from wound contraction, acne scars; resurfacing cosmetic dermabrasion, resurfacing after laser treatment and in association with dermal reconstruction. Additionally the method may be used for cell replacement therapy, including, for example, nerve cell replacement treatment, epithelial cell (such as urothelial cell, buccal mucosal cell and respiratory epithelial cell) replacement treatment, endothelial cell replacement treatment and osteogenic precursor cell replacement treatment.
  • 6. It provides a means to produce a suspension of cells in a ratio to each other comparable with those seen in situ. That is, due to the manner of preparation of the cellular suspension, cells such as keratinocyte basal cells, Langerhans cells, fibroblasts and melanocytes typically have enhanced survival rates in comparison to standard tissue culture techniques, whereby selective cell culture can result in the loss of certain cell types. This has the advantage of allowing for the correct re-pigmentation of skin after a skin graft.
  • 7. It allows faster surgery and healing—thereby reducing trauma for patients during the phase of their medical care.
  • According to the first aspect of the invention there is provided a method for preparing a cell suspension suitable for use in resurfacing and regeneration of damaged tissue.
  • According to this method, tissue (preferably of an autologous nature) is harvested from a patient by means known in the art of tissue grafting. Preferably this is achieved by taking a tissue biopsy. With the harvesting of the biopsy consideration must be given to the depth of the biopsy and the surface area size. The depth and size of the biopsy influence the ease at which the procedure can be undertaken and speed with which a patient recovers from the procedure. In a highly preferred form of the invention the donor site should be chosen to appropriately match the recipient site, for example post-auricular for head and neck, thigh for lower limbs, inner-upper-arm for upper limbs, or palm for sole or vice-versa.
  • Once a biopsy has been harvested from a patient the tissue sample is subjected to physical and/or chemical dissociating means capable of dissociating cellular stratum in the tissue sample.
  • Methods for dissociating cellular layers within the tissues are well known in the field. For example, the dissociating means may be either a physical or a chemical disruption means. Physical dissociation means might include, for example, scraping the tissue sample with a scalpel, mincing the tissue, physically cutting the layers apart, or perfusing the tissue. Chemical dissociation means might include, for example, digestion with enzymes such as trypsin, dispase, collagenase, trypsin-EDTA, thermolysin, pronase, hyaluronidase, elastase, papain and pancreatin. Non-enzymatic solutions for the dissociation of tissue can also be used.
  • Preferably, dissociation of the tissue sample is achieved by placing the sample in a pre-warmed enzyme solution containing an amount of enzyme sufficient to dissociate cellular stratum in the tissue sample. This may be achieved, for example using a trypsin solution, however, any other enzyme such as dispase, collagenase, trypsin-EDTA, thermolysin, pronase, hyaluronidase, pancreatin, elastase and papain that cause cells to become detached from other cells or from solid surfaces may be used for this purpose. When the enzyme used is trypsin the enzyme solution used in the method is preferably calcium and magnesium free. One such solution is preferably calcium and magnesium ion free phosphate buffered saline.
  • Where the tissue biopsy is derived from a patient's skin (comprising epithelial-dermal cells) the amount of trypsin that might be used in the method is preferably between about 5 and 0.1% trypsin per volume of solution. Desirable the trypsin concentration of the solution is about 2.5 to 0.25%, with about 0.5% trypsin being most preferred.
  • The time period over which the tissue sample is subjected to the trypsin solution may vary depending on the size of the biopsy sample taken. Preferably the tissue sample is placed in the presence of the trypsin solution for sufficient time to weaken the cohesive bonding between the tissue stratum. For example, where the tissue sample is taken from a patient's skin the sample might be placed in trypsin for a 5 to 60 minute period. Preferably, the tissue sample is immersed in the trypsin solution for between 10 and 30 minutes with 15 to 20 minutes being optimal for most tissue samples.
  • After the tissue sample has been immersed in the trypsin solution for an appropriate amount of time, the sample is removed from the trypsin and washed with nutrient solution. Washing the tissue sample may involve either partial or complete immersion of the treated sample in the nutrient solution. Alternatively, and more preferably, the wash solution is dripped on the tissue sample in sufficient volume to remove and or significantly dilute any excess trypsin solution from the surface of the sample. Preferably any dilution that might occur would lead to less than 0.05% trypsin in the nutrient solution.
  • The nutrient solution used in the method should be capable of significantly reducing and more preferably removing the effect of the trypsin either by dilution or neutralization. The nutrient solution used in the method will also preferably have the characteristics of being (i) free of at least xenogenic serum, (ii) capable of maintaining the viability of the cells until applied to a patient, and (iii) suitable for direct application to a region on a patient undergoing tissue grafting. The solution may be anything from a basic salt solution to a more complex nutrient solution. Preferably, the nutrient solution is free of all serum but contains various salts that resemble the substances found in body fluids; this type of solution is often called physiological saline. Phosphate or other non-toxic substances may also buffer the solution in order to maintain the pH at approximately physiological levels. A suitable nutrient solution that is particularly preferred is Hartmann's solution.
  • After application of the nutrient solution to the tissue sample, the cellular stratum of the sample are separated permitting cells capable of reproduction to be removed from the cellular material and suspended in the nutrient solution. Where the tissue sample is skin the dermis and epidermis are preferably separated to allow access to the dermal-epithelial junction of both surfaces.
  • Cells capable of reproduction are then removed from the separated stratum by any means known in the art. Preferably, the reproductive cells are scraped off the surface of the stratum using an instrument such as a scalpel. Cells capable of reproduction within the dermal-epithelial junction include but are not limited to keratinocyte basal cells, Langerhans cells, fibroblasts and melanocytes. Following release of the cells from the tissue sample they are suspended in the nutrient solution. Preferably only a small volume of nutrient solution is applied to the tissue sample during this harvesting step otherwise the suspension may become too fluid therein providing difficulties in applying the suspension to the graft.
  • To avoid excessively large cellular congregates in the cellular suspension the suspension is preferably filtered. Any filter capable of separating excessively large cellular congregates from the suspension may be used in this preferred step of the invention. In a highly preferred form of the invention the filter size is between 50 μm and 200 μm. More preferably it is between 75 μm and 150 μm, with 100 μm being one specific example.
  • Prior to application to the graft site or immediately after filtering, the cellular suspension may be diluted to produce an appropriate cell density suitable for the purpose to which the suspension is to be used.
  • According to the second aspect of the invention there is provided an aqueous cell suspension produced by the method described in the first aspect of the invention. The cell suspension provided by this method is highly suitable for tissue regeneration and grafting techniques. An important advantage of utilizing such a suspension in grafting technology is that it can be used to greatly expand the area or volume of a wound that can be treated quickly by in situ multiplication of a limited number of cells. The number and concentration of cells seeded onto graft site may be varied by modifying the concentration of cells in suspension, or by modifying the quantity of suspension that is distributed onto a given area or volume of the graft site.
  • By suspending cells in a nutrient solution which is at least (i) free of xenogenic serum, (ii) capable of maintaining the viability of the cells until applied to a patient and (iii) is suitable for direct application to a region on a patient undergoing tissue grafting, the inventors have found that the outcome of patient grafts is improved. A partial explanation for this appears to be attributable to the removal of xenogenic serum and more preferably all serum from the cell suspension. Xenogenic serum is a common additive in grafting culture medium and is well known to cause potential infective and hypersensitivity problems. Such serum is however generally required for the in vitro expansion of the cells and to neutralize the action of the enzyme if the enzyme used is trypsin. The nutrient solution used in the present invention does not require such serum because the cell population within the suspension is not expanded prior to application to the graft site. Rather cellular multiplication is encouraged on the patient rather than in an in vitro system. When trypsin is used neutralization is achieved by other means.
  • Another unique feature of the cell suspension produced according to the method of the first aspect of the invention is that the composition of cells in the cellular preparation is comparable to that seen in situ compared to prior art cellular preparation. One possible explanation for this is that in the prior art, culture of the cellular preparation utilizes selective culture for keratinocytes, therefore loss of cellular constituents such as fibroblasts and melanocytes occurs whereas the cellular suspension produced from the first aspect of the invention has a cell composition comparable to the in situ cell population. Another feature of the cellular suspension produced from the first aspect of the invention is that the graft cells are more viable as they are harvested in a nutrient solution as distinct from prior art cell harvesting procedures which utilize techniques where the cells are harvested whilst exposed to powerful digestive enzymes for excessive periods of time. When the cells are exposed to such enzymes for excessive periods of time the viability of the cellular suspension decreases.
  • According to the third aspect of the invention there is provided a method of treatment of the patient requiring a tissue graft. By this method the cellular suspension produced according to the first aspect of the invention is applied to a graft site. A liquid suspension containing cells may be manually distributed onto the graft site by any of several techniques, which include spraying, spreading, pipetting and painting.
  • In a highly preferred form of the invention the suspension is sprayed on to a graft site. The suspension may be sprayed through any type of nozzle that transforms liquid into small airborne droplets. This embodiment is subject to two constraints. First, it must not subject the cells in solution to shearing forces or pressures that would damage or kill substantial numbers of cells. Second, it should not require that the cellular suspension be mixed with a propellant fluid that is toxic or detrimental to cells or wound beds. A variety of nozzles that are commonly available satisfy both constraints. Such nozzles may be connected in any conventional way to a reservoir that contains the cellular suspension.
  • Alternatively the suspension may be delivered via a pipette, common “eye-droppers,” syringe and needle and or other similar devices to place small quantities of cellular suspension on a graft site.
  • After the cell suspension has been applied to the recipient graft site, the wound may be dressed with a wound dressing. In a preferred embodiment the dressing is Surfasoft™ a woven nylon dressing. Preferably, the healing of the wound is followed up by standard protocols for skin graft treatment known to those skilled in the art.
  • According to the fourth aspect of the invention there is provided an apparatus for developing a tissue regeneration solution, which has a heating means suitable for heating an enzyme solution to a required temperature and which is capable of maintaining that solution at the desired temperature for a suitable amount of time; and a filter recess comprising a filter means capable of separating large cellular congregates from a cellular suspension.
  • In a preferred form of the fourth aspect of the invention the apparatus also includes a reservoir capable of holding a tissue sample and a nutrient solution which solution is also capable of maintaining the viability of the cells in the tissue sample. More preferably the reservoir is of sufficient size to permit manipulation of the tissue sample permitting separation of the tissue cellular stratum and harvesting of those cells from the stratum suitable for grafting.
  • The apparatus may also include one or more fluid containment wells for storage of fluids such as the nutrient solution. The wells may alternatively serve as a receptacle for a container such as a plastic or glass vial that holds the nutrient solution. Preferably, the well is capable of holding at least a 10 ml volume. Such wells permit ease of fluid application to the tissue sample. Storage of such fluids in close proximity to its site of application also provides the advantage of reducing the risk of accidental leakage of the fluid and provides an easy means for accessing the fluid for accurately delivering it to either the tissue sample or the cell suspension.
  • In a highly preferred form of the invention the apparatus comprises a first and second member wherein:
  • (1) the first member includes:
  • (a) at least a heating means suitable for heating an enzyme solution to a required temperature and which is capable of maintaining that solution at the desired temperature for a suitable amount of time;
  • (b) at least a filter recess comprising a filter means capable of separating large cellular congregates from a cellular suspension;
  • (c) at least a fluid containment well for storage of nutrient solution;
  • (2) the second member forms a reservoir capable of withholding a tissue sample and nutrient solution in fluid containment; and
  • wherein the first member provides a seat upon which the second member may be placed during manipulation of the tissue.
  • In a further preferred form of the invention the first member provides an storage compartment into which tools and solutions used in the above described method may be stored. Where such a compartment is provided in the apparatus the second member may provide the lid or closure to that compartment. In use the lid is preferably removed from the top of the compartment and inverted. The underside of the lid preferably forms the reservoir therein enabling the second member to serve a dual purpose. Tools and solutions used in the method can be accessed from the compartment. The inverted lid may then be seated back over the compartment therein providing the reservoir for the apparatus.
  • The apparatus may be made from metal, plastic or any other material. Further, the container may be any size. Preferably the size of the container is only limited by its intended use and the need for sterilization such as by the use of gamma irradiation and or ethylene oxide.
  • It should be appreciated that the heating means employed in the apparatus may simply constitute a heating pad or pads on the top of the first member. There are however, attendant problems with such arrangements, not least of which is the possibility of accidental spillage of the container undergoing heating. Therefore, in an embodiment, one or more heating means may be housed within a recess in the first member. Also located within that recess is at least a container into which tissue may be placed for exposure to the enzyme solution. In an alternate embodiment one or more heating means may be housed in the base of the apparatus. In such a configuration the first member contains at least an opening suitable for receiving a container capable of holding fluid, which opening provides access for the container to the heating means.
  • It will be appreciated that if the apparatus is designed for more than one use the heating means may be capable of being repeatedly heated and cooled. Alternatively each heating unit may be capable of a single use, but multiple heating units may be provided with the apparatus to facilitate multiple heating events.
  • In a highly preferred configuration of the apparatus a heating collar is located within a recess therein forming a heating recess in the first member within which there is located a container (e.g., a vial) for the enzyme. The container is preferably held in place by at least a restraining means, which desirably surrounds part of the upper portion of the container preventing accidental release of the container from the apparatus. In circumstances, where the apparatus is intended for single use the restraining means may be formed as an integral part of the first member, thus meaning that removal of the container may only be achieved by physically breaking the first member.
  • The heating means used in the apparatus is preferably controlled by circuitry permitting activation of the heating element when required. For example the heating means may be switched on by depressing the start button located, for example, on the surface of the first member. Alternately the heating means may be activated by pushing the container down with sufficient force to activate a switch located in the base of the apparatus. A person of ordinary skill in the field will appreciate that a wide range of electronic means may be used to activate the heating unit provided in the apparatus.
  • Desirably the heating unit is also operably linked to a timer mechanism, which is adapted to heat the enzyme solution for a pre-defined period of time. In circumstances where the apparatus is intended for multiple uses, preferably the timer can be set to deactivate the heating element when a particular amount of time is reached. At which point an alarm may activate to inform the user that the time is up. The alarm may be audible or in the form of a light display.
  • In a further preferred embodiment of the present invention the heating means may be provided with an adjustable temperature control. Where temperature adjustment is required such variation may be achieved by adapting the heating control circuitry to include or communicate with a temperature control mechanism permitting the temperature of the heating unit to be constantly varied within a constant range, or it may present a range of select temperatures that the heating control means can be set at. A temperature control means will beneficially be included in the apparatus where the apparatus is to be used in the harvesting and preparation of different cell types and or where different enzymes are used in the harvesting method for which the apparatus has unique application.
  • In an alternate more preferred form, the apparatus is designed for single use. In such instances the timer mechanism is part of the circuitry that controls the heating means. Once the heating means has been activated it heats the solution for a predefined period of time and then self-destructs. It should be appreciated by those skilled in the art that such an the apparatus may be fitted with various monitoring means that are capable of indicating such things as: the enzyme has reached the required temperature; the amount of time that the enzyme has been in the solution for; and or the amount of time left before the circuitry self-destructs etc. By way of example only, the monitoring means might consist of a series of LED's that activate when certain events occur. In a highly preferred embodiment the heating element preferably remains in the heating mode for a maximum of 45 minutes to 1 hour.
  • The heating means may be powered by any means known in the art. Preferably, the power supply is provided by battery/batteries. In one form of the invention, the power supply is a battery or a plurality of batteries located in the base of the apparatus.
  • In a further embodiment of the invention the apparatus may be provided with one or more means to facilitate mixing of the solutions used in the invention, such as for example an enzyme solution. In this respect, and by way of example only, the apparatus may include a means for vortexing the solution; such as an electromagnetic system that is adapted to agitate a magnetic bead. Where the apparatus includes an electromagnetic mixing system the magnetic bead is preferably provided in the container (e.g., vial) in which the solution is stored in the apparatus. Alternatively the magnetic bead may be added to the solution when mixing is desired.
  • In a highly preferred form of the invention the mixing means is combined with the heating means either as a single unit or as separate units to facilitate constant heating of the solution in an even manner. Using such a mixing means avoids the possible overheating of solution closest to the heating unit while the solution is heated. Such a system will provide a more constant heating of the solution. Alternate means for mixing the solution will be known in the art and include, mechanical, physical, electrical and electromagnetic means as an example. While any mixing means may be employed in the apparatus, preferably the mixing means is either selected to minimize vibration of the apparatus or incorporated into the apparatus in a manner that minimize such vibration. In this respect the mixing means may be housed on one or more vibration dampeners or the apparatus may include one or more vibration dampeners on is base.
  • Where a mixing means is incorporated into the apparatus the means may be automatically activated upon activation of the heating unit or alternatively there may be a separate activation system. Further, the speed of the mixing may either be fixed or variable. Preferably, there is a separate activation system for the mixing means.
  • The filter recess incorporated into the apparatus may be of any size or shape that facilitates filtering of a cellular suspension. Further the recess may be adapted to receive and hold at least a tube into which cell suspension may be filtered. Preferably the recess has a conical base providing easy means to access the full volume of cell suspension after it has been filtered.
  • Desirably, the third recess is designed to receive a 100 μm cell filter. The third recess can accommodate a 100 μm cell filter connected to a conical tube. Preferably, the tube has area/volume graduations marked on the side.
  • The apparatus may also include a set of tools required for cell harvesting. It will be appreciated by those skilled in the art that any tools necessary for cell harvesting may be included with the device. Preferably, the set of tools are sterile. As an example only, the set of tools may include a glass vessel of separation enzyme; a sterile solution for suspension of the enzyme; a sterile nutrient solution; scalpel; forceps; syringe; medicine dropper, cell filter; wound dressings and/or spray nozzles. In a highly preferred embodiment, the set of tools are stored in a compartment formed in the first member of the apparatus, which is covered by the second member when not in use.
  • In a highly preferred embodiment, the device is used to harvest a suspension of cells and apply the cells to a recipient site in the following manner.
  • An aliquot of sterile water is mixed with a portion of lyophilized separation enzyme and placed in the heating recess. The heating means is then activated which heats the contents (i.e. the enzyme solution) of the container to a working temperature of between 30 and 37° C., preferably between 33 and 37° C. and by way of example 37° C. within 2 minutes and maintains the working temperature for at least 45 minutes. Once an operational temperature has been reached, a sample of tissue taken from a donor site is placed in the enzyme solution and incubated at the working temperature. The tissue sample is incubated for between 5 to 45 minutes. Those skilled in the art would appreciate that the time taken to achieve separation of the layers of the tissue sample is dependent on the thickness and size of the tissue sample and the incubation temperature. Once enzymatic separation of the tissue layers is achieved, the tissue sample is removed to the reservoir and the tissue layers are separated using surgical instrument/s.
  • A carefully measured aliquot of the second solution is then withdrawn from the fluid containment well by aspiration into a syringe and then applied to the layers. The cells between the layers of tissue are scraped off and suspended by mixing with the nutrient solution. The cell suspension is then collected, preferably using a syringe and cannula.
  • The harvested suspension of cells is then passed through a cell filter located in the filter recess and the filtered suspension of cells is collected into the filter recess. The reservoir may optionally be rinsed with a further volume of the second solution and this resulting suspension of cells also filtered and collected in the filter recess.
  • The filtered suspension of cells may then optionally be aspirated into a syringe and applied to the recipient site.
  • EXAMPLES
  • Further features of the present invention are more fully described in the following non-limiting Examples. It is to be understood, however, that this detailed description is included solely for the purposes of exemplifying the present invention. It should not be understood in any way as a restriction on the broad description of the invention as set out above.
  • The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compositions and/or methods claimed herein are made and evaluated, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. The present invention is more particularly described in the following examples which are intended as illustrative only since numerous modifications and variations therein will be apparent to those skilled in the art.
  • Example 1 Preparation of Recipient Site
  • To optimize the success of the skin graft, the wound was cleaned and assessed to be of the appropriate depth. Further, blood haemostasis was established and the wound checked for evidence of surrounding cellulitis or infection. Techniques for preparing the area included sharp dissection, dermabrasion or laser-resurfacing.
  • Donor Site Biopsy
  • The donor site was chosen to appropriately match the recipient site. The donor site was infiltrated with local anaesthetic and adrenaline underneath the skin near the subcutaneous tissue. This allowed the donor site to be firm and aided in the taking a thin split-thickness biopsy. The dimensions of the biopsy were determined by the size of the surface area of the recipient site to be covered. Typically, the biopsy size has an expansion ratio of 1:10-1:80. In this case, a biopsy size of 2 cm×2 cm was taken from the donor site giving an expansion ratio of 1:60.
  • Cell Resurfacing Using the Rapid Technique
  • Treatment of the wound was carried out using the Re-Cell® Rapid Technique cell harvesting apparatus, which is explained in more detail in Example 2 below. The apparatus contained all the instruments, solutions, enzymes and dressings required for wound treatment.
  • The heating element was activated by depressing the “start button”. Solution (sterile water for injection) (10 ml) was transferred from the supplied plastic vessel marked Solution A into a glass vessel containing the separation enzyme (lyophilized trypsin) to give a final concentration of 0.5% trypsin. The enzyme solution was then mixed together, transferred to a vessel already located in the heating element recess and heated to 37° C.
  • The vessel containing Solution B (nutrient media) was transferred from its supplied vessel into the fluid containment well.
  • The previously obtained tissue sample was then placed in the enzyme solution and incubated at 37° C. for between 10 to 15 minutes. After this time, the tissue sample was removed from enzyme solution with a pair of forceps, rinsed by dipping into the fluid containment well containing Solution B and placed with the dermal side down and the epidermal side up in the reservoir.
  • Solution B was then aspirated from the well into a syringe and dripped from the syringe onto both layers of the biopsy.
  • The skin layers were separated using forceps. This allowed access to the zone of the dermal-epidermal junction of both surfaces. Cells were scraped from the surfaces to develop a plume of cells in the reservoir. The cells were then mixed in Solution B. The plume of cells was then drawn up into the syringe via a 19 gauge cannula.
  • The supplied filter (100 μm cell filter) was mounted in the filter recess and the plume of cells in Solution B was passed through the filter. A further small amount of Solution B was then used to rinse the reservoir (e.g., a petri dish) and collect any remaining cells, which were also passed through the filter.
  • The resulting suspension of cells collected in the conical recess was aspirated into a syringe and a nozzle was attached to the syringe for spraying or dripping on to the wound area.
  • The wound was re-checked to ensure that it was clean and free of debris and that there was no evidence of bacterial contamination. Further, the wound was checked to determine if haemostasis had been achieved. Once the recipient site was ready, the suspension of cells was applied to the wound surface using the nozzle.
  • The wound was dressed with Surfasoft™ a woven nylon dressing, which was supplied with the apparatus. The healing of the wound was followed up using standard protocols for skin-graft treatment.
  • Example 2
  • The embodiment shown in FIG. 1 is directed to a Re-Cell® Rapid Technique cell harvesting apparatus 10 for use in producing a transplantable cellular suspension of living tissue suitable for grafting to a patient.
  • As illustrated in FIG. 1 the apparatus includes a closure lid 12 possessing a locking mechanism 14 adapted to releasably engage a base portion 16. The locking mechanism 14 provides a means for closing the apparatus 16 when not in use. Located within the base portion 16 is a first member 18 within which there is provided an aperture 20 in which there is located a vial 22 for the enzyme. Adjacent the aperture there is provided an activation switch 24 capable of activating the heating means (not shown). The first member also provides a fluid containment well 26 and a filter recess 28. As presented in this illustration the filter 29 is shown located in the filter recess. Ordinarily the filter is an optional item included as a separate item in the apparatus.
  • The aperture 20 in the first member 18 is desirably of such a diameter that it allows the neck of the vial 22 to protrude through and above the first member 18. The periphery of the aperture 20 is fitted with a collar 21 which is slightly smaller than the diameter of the body of the vial 22. Thus, when in use, the vial 22 cannot be removed from the apparatus 10 as it is held in place by the collar 21 located around the periphery of the aperture 20.
  • Located adjacent to the aperture 20, fluid containment well 26 and filter recess 28 is the second member 30 which is positioned on a seat (not shown) located within a storage compartment (not shown) within the first member 18. When inverted the second member 30 forms a reservoir within which tissue manipulations may be performed. To facilitate separation of the second member 30 from the first member 18 an indent 32 is provided in the side of a portion of the second member 30, which is of such a size that a person can lift the second member from the seat on which it resides in the first member 18.
  • Within the filter recess 28 there is located a filter 29 (provided separately with the other components) having a mesh therein capable of separating cellular material of greater than 100 μm from a cell supernatant.
  • FIG. 2 provides a partially exploded perspective view of the apparatus 10 wherein the second member 30 is removed from the first member 18 and inverted. Inversion of the second member 30 reveals the sidewalls 32 of the second member 30, which form the fluid containment barrier of the reservoir and a reservoir area 34 in which tissue manipulations may be performed.
  • Removal of the second member 30 from the first member 18 also reveals a storage compartment 36 in the first member 18 in which solutions and tools may be stored when the apparatus 10 is not in use. Within the storage compartment 36 there is located a seat 38 upon which the second member 30 may reside. The seat 38 is preferably located around the periphery of the storage compartment 36 at a depth beneath the surface of the first member 18 that is equivalent to the height of the sidewalls 32 of the second member 30.
  • FIG. 3A provides a perspective view of the first member 18 showing the storage compartment 36, the heater activating switch 24, the aperture 20, the fluid containment well 26 and filter recess 28 formed within the first member. FIG. 3B provides a rear view of the first member 18 showing the filter recess 28, the fluid containment well 26, the heater activating switch 24, the aperture collar 21 and the rear wall of the storage compartment 36. As seen in this figure the filter recess has a conical base thereby providing a means for easy access to the cell suspension that is filtered into it. Located adjacent to the fluid containment well and on the opposite side of the filter containment well there is also provided a battery positioning member 40 which protrudes towards the base 16 of the apparatus (not shown) and provides a means for holding the batteries in place, which are required for activating the heating means.
  • FIG. 4 provides a perspective view of the base 16 of the apparatus 10 showing the vial 22 located within a containment field 42. Between the containment field 42 and the vial 22 there is located a heating collar(s) 44, which surrounds the body of the vial. Adjacent the containment field there is a circuit board 46, which is held in position by circuit board containment means 48, 50 and 52. Said circuit board 46 is in electrical communications with the heating collar(s) 44 by wires 54. The circuit board is also in electrical communication via wires 58 with the heater activating switch (not shown). Adjacent the circuit board 46 there is provided a battery containment means 58, which holds 4 AA batteries in immovable position (not shown). The batteries are in electrical communication with the circuit board 46 by wires 60. When the first member 18 is fitted to the base 16 the batteries are held in place by the battery containment means 58, the battery positioning means 40 and the base of each of the fluid containment well 26 and the filter recess 28. Preferably the conical base of the filter recess 28 also protrudes between the batteries therein providing a further means for securing the batteries in immovable position.
  • Modifications and variations of the described methods and device of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in the relevant field in which this invention resides are intended to be within the scope of the following claims.

Claims (19)

1. A method for preparing a cell suspension suitable for application to a patient, comprising the steps of:
(a) harvesting cells suitable for grafting to a patient from a tissue sample from a first tissue region of the patient, wherein a cellular stratum in the tissue sample is physically and/or chemically dissociated, wherein the cells are harvested in a nutrient solution that is (i) free of serum xenogenic to the patient, (ii) capable of maintaining viability of the harvested cells, and (iii) suitable for direct application to a second tissue region of the patient; and
(b) filtering the harvested cells to remove cellular conglomerates greater than 200 μM,
thereby producing a cell suspension comprising viable cells autologous to the patient, wherein the cell suspension is free of serum xenogenic to the patient and free of cellular conglomerates greater than 200 μM.
2. The method according to claim 1 wherein the first tissue region is the same as the second tissue region.
3. The method according to claim 1 wherein the first tissue region is a different region than the second tissue region and is selected to match the second tissue region.
4. The method according to claim 1 further comprising dissociating the harvested cells in a solution comprising an enzyme.
5. The method according to claim 4 wherein the enzyme is selected from the group consisting of trypsin, trypsin-EDTA, dispase, collagenase, thermolysin, pronase, hyaluronidase, pancreatin, elastase and papain.
6. The method according to claim 1 wherein the nutrient solution is Hartmann's solution.
7. The method according to claim 1 further comprising multiplicating cells in situ.
8. A method for delivering a cell suspension to a patient in need of graft surgery, said method comprising the steps of:
(a) harvesting cells suitable for grafting to the patient from a tissue sample of the patient in a nutrient solution that is (i) free of serum xenogenic to the patient, (ii) capable of maintaining viability of the harvested cells, and (iii) suitable for direct application to a second tissue region of the patient;
(b) filtering the harvested cells to remove cellular conglomerates greater than 200 μM to produce a cell suspension; and
(c) administering the cell suspension to a tissue region of the patient in need of a cell graft.
9. The method of claim 8, wherein said administering comprises spreading the cell suspension over the tissue region in a substantially even distribution.
10. The method of claim 9, wherein said spreading comprises spraying or dripping the cell suspension through a nozzle.
11. The method of claim 8 further comprising multiplicating cells in situ.
12. An apparatus for delivering cells to a patient in need of graft surgery, said apparatus comprising an aerosol bottle adapted to deliver a medium comprising a nutrient solution that is (i) free of serum xenogenic to the patient, (ii) capable of maintaining viability of a cell, and (iii) suitable for direct application to a tissue region of the patient; and wherein the medium further comprises cells that are harvested from a tissue sample of the patient and free of cellular conglomerates greater than 200 μM.
13. The apparatus of claim 12, wherein the aerosol bottle comprises a syringe for collecting the medium and a nozzle attached to the syringe for spraying or dripping the medium to the tissue region of the patient.
14. The apparatus of claim 12 further comprising a filter adapted to remove cellular conglomerates greater than 200 μM.
15. An apparatus for developing a solution for tissue regeneration, said apparatus comprising:
(a) a heating means suitable for heating an enzyme solution to a predetermined temperature and capable of maintaining the enzyme solution at the predetermined temperature for a suitable amount of time; and
(b) a filter recess comprising a filter for removing cellular conglomerates greater than 200 μM.
16. The apparatus according to claim 15 further comprising a reservoir adapted to hold a tissue sample and a nutrient solution.
17. The apparatus according to claim 15 further comprising one or more fluid containment wells for storage of fluids.
18. An apparatus for developing a solution for tissue regeneration, said comprising a first and second member, wherein:
(i) the first member comprises:
(a) a heating means suitable for heating an enzyme solution to a predetermined temperature and capable of maintaining the enzyme solution at the predetermined temperature for a suitable amount of time;
(b) a filter recess comprising a filter for removing cellular conglomerates greater than 200 μM from a cellular suspension; and
(c) at least one fluid containment well for storage of a nutrient solution;
(ii) the second member comprises a reservoir capable of holding a tissue sample and a nutrient solution in one or more fluid containment wells;
and wherein the first member provides a seat upon which the second member is placed during manipulation of the tissue sample.
19. A method for expanding a population of cells in situ, the method comprising:
(a) harvesting cells suitable for grafting to a patient from a tissue sample of the patient, wherein a cellular stratum in the tissue sample is physically and/or chemically dissociated, wherein the cells are harvested in a nutrient solution that is (i) free of serum xenogenic to the patient, (ii) capable of maintaining viability of the harvested cells, and (iii) suitable for direct application to a second tissue region of the patient;
(b) filtering the harvested cells to remove cellular conglomerates greater than 200 μM to produce a cell suspension;
(c) applying the cell suspension to a tissue region of the patient in need of a cell graft; and
(d) permitting cells to expand in situ under conditions suitable for cellular multiplication.
US12/699,554 2001-02-07 2010-02-03 Cell Suspension Preparation Technique and Device Abandoned US20100196334A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AUPR2989A AUPR298901A0 (en) 2001-02-07 2001-02-07 Cell suspension preparation technique and device
AUPR2989 2001-02-07
US28152701P true 2001-04-04 2001-04-04
US10/068,299 US20020106353A1 (en) 2001-02-07 2002-02-06 Cell suspension preparation technique and device
US12/699,554 US20100196334A1 (en) 2001-02-07 2010-02-03 Cell Suspension Preparation Technique and Device

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/699,554 US20100196334A1 (en) 2001-02-07 2010-02-03 Cell Suspension Preparation Technique and Device

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/068,299 Continuation US20020106353A1 (en) 2001-02-07 2002-02-06 Cell suspension preparation technique and device

Publications (1)

Publication Number Publication Date
US20100196334A1 true US20100196334A1 (en) 2010-08-05

Family

ID=3827012

Family Applications (7)

Application Number Title Priority Date Filing Date
US10/068,299 Abandoned US20020106353A1 (en) 2001-02-07 2002-02-06 Cell suspension preparation technique and device
US11/518,012 Abandoned US20070042488A1 (en) 2001-02-07 2002-02-07 Cell spraying device, method and sprayed cell suspension
US12/699,554 Abandoned US20100196334A1 (en) 2001-02-07 2010-02-03 Cell Suspension Preparation Technique and Device
US13/036,569 Active US9029140B2 (en) 2001-02-07 2011-02-28 Cell suspension preparation technique and device
US13/223,577 Active US9078741B2 (en) 2001-02-07 2011-09-01 Cell suspension preparation technique and device
US14/645,933 Active US9867692B2 (en) 2001-02-07 2015-03-12 Cell suspension preparation technique and device
US15/838,429 Pending US20180098840A1 (en) 2001-02-07 2017-12-12 Cell Suspension Preparation Technique and Device

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/068,299 Abandoned US20020106353A1 (en) 2001-02-07 2002-02-06 Cell suspension preparation technique and device
US11/518,012 Abandoned US20070042488A1 (en) 2001-02-07 2002-02-07 Cell spraying device, method and sprayed cell suspension

Family Applications After (4)

Application Number Title Priority Date Filing Date
US13/036,569 Active US9029140B2 (en) 2001-02-07 2011-02-28 Cell suspension preparation technique and device
US13/223,577 Active US9078741B2 (en) 2001-02-07 2011-09-01 Cell suspension preparation technique and device
US14/645,933 Active US9867692B2 (en) 2001-02-07 2015-03-12 Cell suspension preparation technique and device
US15/838,429 Pending US20180098840A1 (en) 2001-02-07 2017-12-12 Cell Suspension Preparation Technique and Device

Country Status (6)

Country Link
US (7) US20020106353A1 (en)
EP (1) EP2957288A1 (en)
AU (1) AUPR298901A0 (en)
BR (1) BRPI0206692B1 (en)
ES (1) ES2534353T3 (en)
PT (1) PT2343079E (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110150848A1 (en) * 2001-02-07 2011-06-23 Wood Fiona M Cell Suspension Preparation Technique and Device
WO2017120493A1 (en) * 2016-01-06 2017-07-13 The Research Foundation For The State University Of New York Liquid tissue graft
WO2018092149A1 (en) * 2016-11-15 2018-05-24 Regenerative Medical Services Pvt. Ltd A process for preparing buccal epithelial cell suspension and its use

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004280616A1 (en) 2003-10-08 2005-04-21 Vet-Stem Inc. Methods of preparing and using stem cell compositions and kits comprising the same
DE102007040252A1 (en) * 2006-09-11 2008-06-12 Gerlach, Jörg, Prof. Dr. Device for electronically flow-controlled distribution of tissue regenerating cell in sterile suspension across an area for further growth comprises electronically pressure/flow controlled spray head enabling controlled pump driven spraying
CN101605566A (en) * 2006-10-13 2009-12-16 利莱恩斯生命科学有限公司 Cultured melanocytes on biopolymers
US20110059182A1 (en) * 2008-02-05 2011-03-10 University Of Virginia Patent Foundation Spraying device and related method for cell aggregates and cell aggregate suspension thereof
EP2575913B1 (en) * 2010-05-25 2018-07-25 Cook Biotech Incorporated Methods, substrates, and systems useful for cell seeding of medical grafts
DE102011100450B8 (en) * 2011-04-27 2013-10-17 Jörg Gerlach Apparatus for spraying of cells, production of the apparatus, method for spraying with the apparatus and a cell suspension is sprayed with the apparatus
US20150079153A1 (en) * 2012-03-22 2015-03-19 Avita Medical Ltd. Cell Suspension and Use Thereof
FR2991690A1 (en) * 2012-06-07 2013-12-13 Genevrier Lab Using a heater to promote biological reaction
CN103810779A (en) * 2014-02-13 2014-05-21 郭任 Bluetooth low-power-consumption lock cylinder
US20150265654A1 (en) * 2014-03-20 2015-09-24 Patrick J. Casey Method for the treatment of damaged tissue
US20160177250A1 (en) * 2014-06-25 2016-06-23 Cytori Therapeutics, Inc. Tissue transfer system
CN104232475B (en) * 2014-09-17 2017-01-11 中国人民解放军第二军医大学 A Fast instant isolated human skin epidermal cells, melanocytes and fibroblasts apparatus and method of

Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1356794A (en) * 1919-12-27 1920-10-26 Smith John Thomas Skid-oiler
US3608553A (en) * 1969-09-04 1971-09-28 Ultrasonic Systems Ultrasonic method and apparatus for tissue grafting
US3647632A (en) * 1968-04-11 1972-03-07 Little Inc A Apparatus for cell culture
US3860706A (en) * 1972-05-24 1975-01-14 Dauch Seiyaku Company Limited Method for curing stock symptoms
US4059486A (en) * 1976-11-03 1977-11-22 Monsanto Company Cell culture process
US4254226A (en) * 1979-09-13 1981-03-03 Sloan Kettering Institute For Cancer Research Process for growing human epidermal cells in tissue culture
US4304866A (en) * 1979-11-14 1981-12-08 Massachusetts Institute Of Technology Transplantable sheets of living keratinous tissue
US4350768A (en) * 1980-09-19 1982-09-21 Bristol Myers Company Method for preparing single cell suspension
US4418691A (en) * 1981-10-26 1983-12-06 Massachusetts Institute Of Technology Method of promoting the regeneration of tissue at a wound
US4458678A (en) * 1981-10-26 1984-07-10 Massachusetts Institute Of Technology Cell-seeding procedures involving fibrous lattices
US4510144A (en) * 1981-08-26 1985-04-09 Newport Pharmaceuticals International Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives
US4533635A (en) * 1979-07-13 1985-08-06 Institut National De La Sante Et De La Recherche Medicale Process for stimulating the growth of epidermal cells
US4649115A (en) * 1983-03-31 1987-03-10 Sloan-Kettering Institute Monoclonal antibodies to skin cells
US4769317A (en) * 1983-06-14 1988-09-06 Hefton John M Process for growing human epidermis, product thereof
US5000963A (en) * 1983-06-14 1991-03-19 Hefton John M Method of treating the skin using human epidermal sheets
US5079160A (en) * 1987-06-08 1992-01-07 Lacy Paul E Method to isolate clusters of cell subtypes from organs
US5145770A (en) * 1990-06-04 1992-09-08 Biosurface Technology, Inc. Cryopreservation of cultured epithelial sheets
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
US5328695A (en) * 1983-03-22 1994-07-12 Massachusetts Institute Of Technology Muscle morphogenic protein and use thereof
US5334527A (en) * 1987-10-14 1994-08-02 Board Of Regents, The University Of Texas System Epidermal graft system
US5352668A (en) * 1991-03-26 1994-10-04 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Product and method for improving keratinocyte adhesion to the dermis
US5352806A (en) * 1992-04-17 1994-10-04 Abbott Laboratories Taxol derivatives
US5441539A (en) * 1985-06-06 1995-08-15 Thomas Jefferson University Endothelial cell deposition device
US5460939A (en) * 1986-04-18 1995-10-24 Advanced Tissue Sciences, Inc. Temporary living skin replacement
US5556783A (en) * 1991-03-27 1996-09-17 Trustees Of Univ. Of Penna Methods of culturing and modulating the growth of hair follicular stem cells
US5601728A (en) * 1994-08-30 1997-02-11 Becton, Dickinson And Company Cell strainer assembly and method of use
US5786207A (en) * 1997-05-28 1998-07-28 University Of Pittsburgh Tissue dissociating system and method
US5814511A (en) * 1994-09-16 1998-09-29 Michigan State University Human breast epithelial cell type with stem cell and luminal epithelial cell characteristics
US5866167A (en) * 1991-11-20 1999-02-02 N.V Innogentics S.A. Non-viable total keratinocyte lysate for promoting wound healing
US5955343A (en) * 1992-12-28 1999-09-21 Massachusetts Institute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US6080581A (en) * 1998-07-02 2000-06-27 Charles Daniel Anderson Culture vessel for growing or culturing cells, cellular aggregates, tissues and organoids and methods for using same
US6207451B1 (en) * 1998-09-15 2001-03-27 The Regents Of The University Of Michigan Mammalian muscle construct and method for producing same
US20020106353A1 (en) * 2001-02-07 2002-08-08 Wood Fiona M. Cell suspension preparation technique and device
US6432666B1 (en) * 1996-05-29 2002-08-13 The Corporation Of The Trustees Of The Sisters Of Mercy In Queensland Dendritic cell receptor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377010A (en) * 1978-11-08 1983-03-22 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Biocompatible material comprising a base polymer bulk graft polymerized with an ethylenically unsaturated carboxylic acid
JPH0372872A (en) 1988-07-12 1991-03-28 Bio Kagaku Kenkyusho:Kk Serum-free culture medium and method for culturing cell of mammals using the same
GB8816516D0 (en) * 1988-07-12 1988-08-17 Welsh Water Authority Portable incubator and incubating kit
US5139031A (en) * 1989-09-18 1992-08-18 La Mina Ltd. Method and device for cytology and microbiological testing
EP0444270A1 (en) * 1990-02-26 1991-09-04 Thomas Jefferson University Endothelial cell deposition device
WO1994025785A1 (en) * 1993-05-05 1994-11-10 Negrotti David F Modular laboratory equipment and coupling system
US5571083A (en) * 1994-02-18 1996-11-05 Lemelson; Jerome H. Method and system for cell transplantation
US5507385A (en) * 1994-08-12 1996-04-16 Rubbermaid Incorporated Multipurpose storage bin
US6238908B1 (en) * 1995-06-07 2001-05-29 Aastrom Biosciences, Inc. Apparatus and method for maintaining and growth biological cells
US5851522A (en) 1995-06-07 1998-12-22 Trustees Of Tufts College Enhancing keratinocyte migration
BR9612256B1 (en) * 1995-12-21 2010-08-10 improved method for immortalizing human skin cells and culture medium.
DE29609565U1 (en) * 1996-05-29 1996-08-22 Heisig Udo Gmbh Tubular film cover for medical equipment
AU3990197A (en) * 1996-10-04 1998-04-09 Metropolitan Health Service Board Method of engraftment of cultured cells
IL120909D0 (en) 1997-05-26 1997-09-30 Lrr & D Ltd Compositions and means for the treatment of burns and other cutaneous traumas
AU740913B2 (en) 1997-09-11 2001-11-15 Purdue Research Foundation Galactosidase modified submucosal tissue
AU1664299A (en) 1997-10-25 1999-05-17 Roche Diagnostics Gmbh Autodegradable microcarriers and their use
AT236669T (en) * 1998-11-30 2003-04-15 Isotis Nv artificial skin
JP2002531176A (en) * 1998-12-02 2002-09-24 ブリストル−マイヤーズ スクイブ カンパニー Spray transport of cell
DE19958693C2 (en) * 1999-12-06 2002-07-18 Biotissue Technologies Gmbh Methods and compositions for the production of cell transplants
AU2451902A (en) * 2000-07-21 2002-02-05 Atropos Ltd A surgical instrument
US7628780B2 (en) * 2001-01-13 2009-12-08 Medtronic, Inc. Devices and methods for interstitial injection of biologic agents into tissue
US7655465B2 (en) 2004-06-07 2010-02-02 Massachusetts Institute Of Technology Methods for ex vivo propagation of somatic hair follicle stem cells
US9259445B2 (en) 2006-06-07 2016-02-16 Universidad Tecnica Federico Santa Maria Integrated implant system (IIS) biocompatible, biodegradable and bioactive, comprising a biocompatible sterile porous polymeric matrix and a gel, integrating in situ the tridimensional matrix structure
US20070286880A1 (en) 2006-06-08 2007-12-13 Andrey Vasiliev Inoculated spongiform scaffold for transplantation and tissue regeneration
WO2008086358A1 (en) 2007-01-08 2008-07-17 University Of Southern California Usc Stevens Skin wound healing compositions and methods of use thereof
US8207118B2 (en) 2009-07-17 2012-06-26 University Of Southern California Skin wound healing compositions and methods of use thereof

Patent Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1356794A (en) * 1919-12-27 1920-10-26 Smith John Thomas Skid-oiler
US3647632A (en) * 1968-04-11 1972-03-07 Little Inc A Apparatus for cell culture
US3608553A (en) * 1969-09-04 1971-09-28 Ultrasonic Systems Ultrasonic method and apparatus for tissue grafting
US3860706A (en) * 1972-05-24 1975-01-14 Dauch Seiyaku Company Limited Method for curing stock symptoms
US4059486A (en) * 1976-11-03 1977-11-22 Monsanto Company Cell culture process
US4533635A (en) * 1979-07-13 1985-08-06 Institut National De La Sante Et De La Recherche Medicale Process for stimulating the growth of epidermal cells
US4254226A (en) * 1979-09-13 1981-03-03 Sloan Kettering Institute For Cancer Research Process for growing human epidermal cells in tissue culture
US4304866A (en) * 1979-11-14 1981-12-08 Massachusetts Institute Of Technology Transplantable sheets of living keratinous tissue
US4350768A (en) * 1980-09-19 1982-09-21 Bristol Myers Company Method for preparing single cell suspension
US4510144A (en) * 1981-08-26 1985-04-09 Newport Pharmaceuticals International Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives
US4418691A (en) * 1981-10-26 1983-12-06 Massachusetts Institute Of Technology Method of promoting the regeneration of tissue at a wound
US4458678A (en) * 1981-10-26 1984-07-10 Massachusetts Institute Of Technology Cell-seeding procedures involving fibrous lattices
US5328695A (en) * 1983-03-22 1994-07-12 Massachusetts Institute Of Technology Muscle morphogenic protein and use thereof
US4649115A (en) * 1983-03-31 1987-03-10 Sloan-Kettering Institute Monoclonal antibodies to skin cells
US4769317A (en) * 1983-06-14 1988-09-06 Hefton John M Process for growing human epidermis, product thereof
US5000963A (en) * 1983-06-14 1991-03-19 Hefton John M Method of treating the skin using human epidermal sheets
US5441539A (en) * 1985-06-06 1995-08-15 Thomas Jefferson University Endothelial cell deposition device
US5460939A (en) * 1986-04-18 1995-10-24 Advanced Tissue Sciences, Inc. Temporary living skin replacement
US5079160A (en) * 1987-06-08 1992-01-07 Lacy Paul E Method to isolate clusters of cell subtypes from organs
US5334527A (en) * 1987-10-14 1994-08-02 Board Of Regents, The University Of Texas System Epidermal graft system
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
US5145770A (en) * 1990-06-04 1992-09-08 Biosurface Technology, Inc. Cryopreservation of cultured epithelial sheets
US5352668A (en) * 1991-03-26 1994-10-04 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Product and method for improving keratinocyte adhesion to the dermis
US5556783A (en) * 1991-03-27 1996-09-17 Trustees Of Univ. Of Penna Methods of culturing and modulating the growth of hair follicular stem cells
US5866167A (en) * 1991-11-20 1999-02-02 N.V Innogentics S.A. Non-viable total keratinocyte lysate for promoting wound healing
US5352806A (en) * 1992-04-17 1994-10-04 Abbott Laboratories Taxol derivatives
US5955343A (en) * 1992-12-28 1999-09-21 Massachusetts Institute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5601728A (en) * 1994-08-30 1997-02-11 Becton, Dickinson And Company Cell strainer assembly and method of use
US5814511A (en) * 1994-09-16 1998-09-29 Michigan State University Human breast epithelial cell type with stem cell and luminal epithelial cell characteristics
US6432666B1 (en) * 1996-05-29 2002-08-13 The Corporation Of The Trustees Of The Sisters Of Mercy In Queensland Dendritic cell receptor
US5786207A (en) * 1997-05-28 1998-07-28 University Of Pittsburgh Tissue dissociating system and method
US6080581A (en) * 1998-07-02 2000-06-27 Charles Daniel Anderson Culture vessel for growing or culturing cells, cellular aggregates, tissues and organoids and methods for using same
US6207451B1 (en) * 1998-09-15 2001-03-27 The Regents Of The University Of Michigan Mammalian muscle construct and method for producing same
US20020106353A1 (en) * 2001-02-07 2002-08-08 Wood Fiona M. Cell suspension preparation technique and device
US20110150848A1 (en) * 2001-02-07 2011-06-23 Wood Fiona M Cell Suspension Preparation Technique and Device

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Understanding mesh sizes." ESPI Metals, online at http://www.espimetals.com/index.php/online-catalog/334-understanding-mesh-sizes. 1 page. *
Adams BF et al. 2000. The role of respiratory epithelium in a rat model of obliterative airway disease. Transplantation 69: 661-693. *
Adams BF et al. 2000. The role of respiratory epithelium in a rat model of obstructive airway disease. Transplantation 69: 661-664, abstract only. *
Atala A et al. 1992. Formation of urothelial structures in vivo from dissociated cells attached to biodegradable polymer scaffolds in vitro. J Urol 148: 658-662. *
Atala A et al. 1992. Formation of urothelial structures in vivo from dissociated cells attached to biodegradable polymer scaffolds in vitro. Journal of Urology 148: 658-662, abstract only. *
Eisinger M et al. 1979. Human epidermal cell cultures: Growth and differentiation in the absence of dermal components or medium supplements. Proceedings of the National Academy of Sciences 76: 5340-5344 *
Fraulin FOG et al. 1998. Autotransplantation of epithelial cells in the pig via an aerosol vehicle. J Burn Care Rehabil 19: 337-345. *
Hicks W et al. 1997. Isolation and characterization of basal cells from human upper respiratory epithelium. Exp Cell Res 237: 357-363. *
Hunyadi J et al. 1987. Keratinocyte grafting: Covering of skin defects by separated autologous keratinocytes in a fibrin net. Journal of Investigative Dermatology 89: 119-120 *
Shore JW et al. 1992. Results of buccal mucosal grafting for patients with medically controlled ocular cicatricial pemphigoid. Ophthalmology 99: 383-395. *
Wenkel H et al. 2000. Long term results after autologous nasal mucosal transplantation in severe mucus deficiency syndromes. British Journal of Ophthalmology 84: 279-284. *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110150848A1 (en) * 2001-02-07 2011-06-23 Wood Fiona M Cell Suspension Preparation Technique and Device
US9029140B2 (en) 2001-02-07 2015-05-12 Avita Medical Limited Cell suspension preparation technique and device
US9078741B2 (en) 2001-02-07 2015-07-14 Avita Medical Limited Cell suspension preparation technique and device
US9867692B2 (en) 2001-02-07 2018-01-16 Avita Medical Ltd. Cell suspension preparation technique and device
WO2017120493A1 (en) * 2016-01-06 2017-07-13 The Research Foundation For The State University Of New York Liquid tissue graft
WO2018092149A1 (en) * 2016-11-15 2018-05-24 Regenerative Medical Services Pvt. Ltd A process for preparing buccal epithelial cell suspension and its use

Also Published As

Publication number Publication date
US20110311497A1 (en) 2011-12-22
BRPI0206692B1 (en) 2018-06-19
AUPR298901A0 (en) 2001-03-08
US20020106353A1 (en) 2002-08-08
US20180098840A1 (en) 2018-04-12
US20150182739A1 (en) 2015-07-02
US9867692B2 (en) 2018-01-16
US9078741B2 (en) 2015-07-14
ES2534353T3 (en) 2015-04-21
US20110150848A1 (en) 2011-06-23
US20070042488A1 (en) 2007-02-22
PT2343079E (en) 2015-07-16
US9029140B2 (en) 2015-05-12
EP2957288A1 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
Billingham et al. Studies on the conservation of epidermal specificities of skin and certain mucosas in adult mammals
Billingham et al. The technique of free skin grafting in mammals
Bello et al. Tissue-engineered skin
Billingham et al. Transplantation studies on sheets of pure epidermal epithelium and on epidermal cell suspensions
EP0644929B1 (en) System and method for transplantation of cells
US6057148A (en) Apparatus for preparing skin cell culture
KR101007625B1 (en) Directed tissue growth employing reduced pressure
US4721096A (en) Process for replicating bone marrow in vitro and using the same
US7364565B2 (en) Controlled enzymatic removal and retrieval of cells
RU2104039C1 (en) Live skin substituent, method of its preparing and method of live skin lesion treatment
JP4447916B2 (en) The method of producing a micro-organ processing system and the micro-organ using the same
US5639654A (en) Process for creating a skin substitute and the resulting skin substitute
EP1443988B1 (en) Device for controlled enzymatic removal and retrieval of tissue
Wood et al. The use of a non-cultured autologous cell suspension and Integra® dermal regeneration template to repair full-thickness skin wounds in a porcine model: a one-step process
US5665391A (en) Cultured, full-thickness integument substitutes based on three-dimensional matrix membranes
Thornton et al. The regeneration of accessory limb parts following epidermal cap transplantation in urodeles
US4505266A (en) Method of using a fibrous lattice
JP3809848B2 (en) Wound treatment with vacuum
Jones et al. A guide to biological skin substitutes
US20030125782A1 (en) Methods for the regeneration of bone and cartilage
US7666192B2 (en) Skin grafting devices and methods
US20150238214A1 (en) Method and Apparatus for Tissue Grafting and Copying
USRE35399E (en) Composite living skin equivalents
US4919664A (en) Stimulation of hair growth
You et al. Cell therapy for wound healing

Legal Events

Date Code Title Description
AS Assignment

Owner name: MCCOMB FOUNDATION, INC., AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STONER, MARIE L.;WOOD, FIONA M.;REEL/FRAME:024441/0541

Effective date: 20021101

AS Assignment

Owner name: AVITA MEDICAL LTD, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE MCCOMB FOUNDATION, INC.;REEL/FRAME:027297/0634

Effective date: 20110925

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: AVITA MEDICAL LTD, CALIFORNIA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME FROM AND PROPERTY DETAILS LISTED ON SCHEDULE A PREVIOUSLY RECORDED ON REEL 027297 FRAME 0634. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECTIVE ASSIGNMENT;ASSIGNOR:MCCOMB FOUNDATION INC;REEL/FRAME:047445/0441

Effective date: 20110925

Owner name: MCCOMB FOUNDATION INC, AUSTRALIA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE FIRST ASSIGNOR'S NAME AND ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 024441 FRAME: 0541. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:STONER, MARIE L.;WOOD, FIONA M.;REEL/FRAME:048099/0153

Effective date: 20021101